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In this study, we assessed association of genome-wide association studies (GWAS) “hits”
by race with adjustment for potential population stratiﬁcation (PS) in two large, diverse
study populations; the Carolina Breast Cancer Study (CBCS; N total=3693 individuals) and
the University of Pennsylvania Study of Clinical Outcomes, Risk, and Ethnicity (SCORE; N
total=1135 individuals). In both study populations, 136 ancestry information markers and
GWAS “hits” (CBCS: FGFR2, 8q24; SCORE: JAZF1, MSMB, 8q24) were genotyped. Prin-
cipal component analysis was used to assess ancestral differences by race. Multivariable
unconditional logistic regression was used to assess differences in cancer risk with and
without adjustment for the ﬁrst ancestral principal component (PC1) and for an interaction
effect between PC1 and the GWAS “hit” (SNP) of interest. PC1 explained 53.7% of the
variance for CBCS and 49.5% of the variance for SCORE. European Americans and African
Americans were similar in their ancestral structure between CBCS and SCORE and cases
and controls were well matched by ancestry. In the CBCS European Americans, 9/11 SNPs
were signiﬁcant after PC1 adjustment, but after adjustment for the PC1 by SNP interac-
tion effect, only one SNP remained signiﬁcant (rs1219648 in FGFR2); for CBCS African
Americans, 6/11 SNPs were signiﬁcant after PC1 adjustment and after adjustment for the
PC1 by SNP interaction effect, all six SNPs remained signiﬁcant and an additional SNP
now became signiﬁcant. In the SCORE European Americans, 0/9 SNPs were signiﬁcant
after PC1 adjustment and no changes were seen after additional adjustment for the PC1
by SNP interaction effect; for SCORE African Americans, 2/9 SNPs were signiﬁcant after
PC1 adjustment and after adjustment for the PC1 by SNP interaction effect, only one SNP
remained signiﬁcant (rs16901979 at 8q24).We show that genetic associations by race are
modiﬁed by interaction between individual SNPs and PS.
Keywords: population stratiﬁcation, ancestry, prostate cancer, breast cancer, GWAS “hits”
INTRODUCTION
Multiple genome-wide association studies (GWAS) have now
been performed for many complex diseases including breast and
prostate cancers. The vast majority of these studies have been per-
formed in individuals of European ancestry only; breast cancer
(Easton et al., 2007; Hunter et al., 2007; Stacey et al., 2007; Gold
et al., 2008; Ahmed et al., 2009; Thomas et al., 2009; Zheng et al.,
2009c) and prostate cancer (Amundadottir et al.,2006; Freedman
et al., 2006; Duggan et al., 2007; Gudmundsson et al., 2007, 2009;
Haiman et al., 2007; Yeager et al., 2007, 2009; Sun et al., 2008;
Thomas et al., 2008; Al Olama et al., 2009; Eeles et al., 2009; Hsu
et al., 2009; Lou et al., 2009; Zheng et al., 2009a). Hence, further
study of these GWAS “hits” in different racial/ethnic groups is
warranted.
While it is now standard practice to test for population stratiﬁ-
cation (PS) and remove ancestral outliers from analysis in GWAS
studies, further adjustment for PS may be necessary when study-
ing a recently admixed population such as African Americans or
Hispanic Americans (Barnholtz-Sloan et al., 2008; Tiwari et al.,
2008). In addition, because risk allele frequencies can vary by
ancestral group, interaction effects between a SNP of interest and
PSmaybeneededinordertofullyunderstanddifferencesinpoten-
tialgeneticassociationsbyrace.Theobjectiveof thecurrentstudy
was to validate potential GWAS “hit” associations in two large,
diverse study populations of breast cancer and prostate cancer,
and to evaluate adjustments for potential PS in association testing
of GWAS“hits”within each study.
MATERIALS AND METHODS
CAROLINA BREAST CANCER STUDY STUDY POPULATION
The CBCS is a population-based case–control study of breast can-
cer conducted in North Carolina (as described in Millikan et al.,
2003).Brieﬂy,eligiblecasesincludedwomenages20–74whowere
diagnosed with primary invasive breast cancer from 1993 to 2001
and lived within a 24-county study area. Cases were identiﬁed
using rapid case ascertainment in cooperation with the North
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Carolina Central Cancer Registry. Randomized recruitment was
used to oversample African Americans and women younger than
50years of age. Women diagnosed with breast carcinoma in situ
(CIS) from 1996 to 2001 were also enrolled in the study. Eligi-
ble controls were women aged 20–74years, residing within the
study area, with no history of breast cancer and were identiﬁed
using Division of Motor Vehicles lists (for women under 65) and
Medicarerecords(forwomenage65–74).Controlswerefrequency
matched to cases according to race within 5year age categories.
Women who agreed to participate in the study provided informed




invasive cases and controls were 76 and 55%, respectively, and for
CIS cases and controls were 83 and 65%, respectively. The ﬁnal
study population consisted of 3693 individuals, 2319 European
Americans (62.8%), and 1374 African Americans (37.2%); 1946
(52.7%) cases and 1747 (47.3%) controls. Fifty-three (N =53;
<2%) individuals were excluded who reported as “other” race
(Hispanic, mixed race or other). Age was deﬁned as age in years
at breast cancer diagnosis for cases or at the time of sampling for
controls. Self-identiﬁed race was reported by each study partici-
pant during the study interview. An offset variable to account for
the sampling design was included in the analysis. All study proce-
duresinvolvinghumansubjectswereapprovedbytheUniversityof
North Carolina (UNC) at Chapel Hill Institutional Review Board.
STUDY OF CLINICAL OUTCOMES, RISK, AND ETHNICITY AT THE
UNIVERSITY OF PENNSYLVANIA
Incident prostate cancer cases were identiﬁed through Urologic
Oncology Clinics at multiple hospitals of the University of Penn-
sylvania Health System (UPHS) between 1995 and 2008 and
includedintheSCOREstudy.ControlsweremenattendingUPHS
general medicine clinics and were ascertained concurrently with
the prostate cancer cases (i.e., between 1995 and 2008) and were
frequency matched to cases according to race. All study partici-
pants provided informed consents. Three hundred ﬁve (N =305;
20%) individuals were excluded as they were of “other” race, or
they had missing genotype data for ancestry estimation. Our ﬁnal
study population consisted of 1135 individuals, 713 European
Americans (62.8%), and 422 African Americans (37.2%); 808
(71.1%)werecasesand327(28.9%)werecontrols.Agewasdeﬁned
as age at consent for both cases and controls. Self-identiﬁed race
wasreportedbyeachstudyparticipantduringthestudyinterview.
All study procedures involving human subjects were approved by
the University of Pennsylvania Institutional Review Board.
GENOTYPING RESULTS
A panel of 200 ancestry informative markers (AIMs) was geno-
typed as part of a multiplex, custom candidate gene SNP panel
assay using the Illumina Goldengate platform for all 3693 CBCS
and all 1165 SCORE individuals (Illumina, Inc., San Diego, CA,
USA; Barnholtz-Sloan et al., 2010); previous studies have shown
that at least 50–100 AIMs are needed to accurately assign one’s
individual ancestry; fewer markers when the average allele fre-
quency difference between ancestral populations 0.6 and above
(Risch et al., 2002; Tsai et al., 2005; Choudhry et al., 2006). AIMs
were selected to maximize the difference in allele frequencies
between ancestral populations and the Fisher’s information cri-
terion (FIC; Pfaff et al., 2004) for distinguishing between African
and European ancestry, based upon ancestral allele frequencies
fromAfrican(YRI)andEuropean(CEU)populationsinHapMap
(www.hapmap.org). AIMs were prioritized based on having the
highest FIC values in the following order: 90% European/10%
African, 10% European/90% African, and 50% European/50%
African. This prioritization allowed theAIMs to be chosen to rep-
resentthewholeexpectedancestraldistributionofthispopulation.
In the CBCS dataset, 42 AIMs SNPs were dropped by Illumina
and 14 failed genotyping resulting in 144 genotyped AIMs. In the
SCORE dataset, 42 SNPs were dropped by Illumina, and 9 failed
genotyping, resulting in 149 genotyped AIMs. There were 136
AIMs in common between the ﬁnal CBCS and SCORE datasets,
and these AIMS were used in the analysis.
Inaddition,forCBCSthecustomIlluminaSNPpanelincluded
many SNPs in breast cancer candidate genes including SNPs
in known GWAS hit genes/regions, FGFR2 and 8q24, and for
SCORE the custom Illumina SNP panel included many SNPs in
prostate cancer candidate genes including SNPs in known GWAS
hit genes/regions,MSMB (rs7920517 only),and 8q24. Some SNPs
for SCORE were genotyped using Taqman (JAZF1, MSMB). For
CBCSall1946casesand1747controlsweregenotypedfor11breast
cancer GWAS SNPs. For SCORE, only 597 cases and 322 controls
were genotyped for 9 prostate cancer GWAS SNPs (88.8% of the
total SCORE sample). For each of these GWAS hit genes/regions,
10/11SNPsinFGFR2 and1/1SNPsin8q24forCBCSand1/1SNPs
in JAZF1, 5/5 SNPs in MSMB and 3/3 SNPs in 8q24 for SCORE
passedeachstudy’srespectivequalitycontrolcriteriaforsuccessful
genotyping and were included for analysis. Further details regard-
ingthegenotypingcallratesforbothdatasetshavebeenpublished
elsewhere (Barnholtz-Sloan et al.,2010; Chang et al.,2011).
STATISTICAL ANALYSIS
Population stratiﬁcation for each study population was assessed
using a multi-pronged approach using the 136 AIM panel strat-
iﬁed by study site (CBCS or SCORE). First, principal compo-
nents analysis was used to assess overall similarities of European
Americans and Africans Americans by study site via scatter plots
of the ﬁrst principal component (PC1) versus the second prin-
cipal component (PC2) using R. Second, principal components
analysis was used to assess PS by race and case–control status via
scatter plots of PC1 versus PC2 using R-based programs. Finally,
we conducted a set of analyses using multivariable unconditional
logistic regression for top breast cancer GWAS“hits,”in the CBCS
case–control data,and for top prostate cancer GWAS“hits,”in the
SCORE case–control data, with and without adjustment for PC1
and also for PC1 by GWAS “hit” interaction effects, generating
odds ratios (OR) and 95% conﬁdence intervals (95% CI) using
R-based programs and SAS version 9.2.
RESULTS
WeﬁrstcomparedtheallelefrequenciesforthetestedGWAS“hits”
in the CBCS and SCORE studies by race to the HapMap African
Yorubans (YRI; as compared to African Americans) and CEPH
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Europeans (CEU; as compared to European Americans; Table 1).
ForCBCSAfricanAmericans,allelefrequenciesforsixof theSNPs
varied from YRI by more than 5%, while for CBCS European
Americans, none of the allele frequencies varied from CEU by
more than 5%. For SCORE African Americans, allele frequencies
for six of the SNPs varied from YRI by more than 5%, while for
SCORE European Americans, allele frequencies for three of the
SNPs varied from CEU by more than 5%.
PC1 explained 53.7% of the variance in ancestry for CBCS
and 49.5% of the variance in ancestry for SCORE. As seen
with the joint analysis, the remaining PCs each accounted for
<1% of the variance for each study site individually. Figure 1
shows the ancestral structure for CBCS and SCORE separately
by race via principal components analysis. PC1 in both sam-
ples can be interpreted as the African axis of ancestral varia-
tion. Both panels of Figure 1 showed that in this joint analysis,



















CBCS rs2981582 FGFR2 C 0.49 0.54 0.53 0.59
rs1219648 A 0.54 0.54 0.57 0.59
rs2420946 C 0.40 0.54 0.48 0.59
rs11200014 G 0.76 0.53 0.80 0.57
rs2981579 C 0.33 0.54 0.40 0.57
rs2162540 A 0.43 0.55 0.49 0.59
rs3135718 A 0.37 0.57 0.44 0.59
rs2936870 C 0.36 0.58 0.43 0.58
rs2912774 C 0.38 0.54 0.44 0.58
rs1896395 C 0.75 1.00 0.80 0.99
rs13281615 8q24 A 0.57 0.54 0.56 0.58
SCORE rs1447295 8q24 C 0.61 0.93 0.70 0.99
rs4242384 A 0.82 0.93 0.84 0.90
rs16901979 C 0.46 0.98 0.55 0.95
rs10486567 JAZF1 C 0.10 0.75 0.73 0.78
rs7920517 MSMB G 0.19 0.42 0.72 0.51
rs10993994 T 0.29 0.34 0.63 0.45
rs7904463 C 0.27 0.62 0.33 0.66
rs10740051 G 0.94 0.66 0.89 0.70
rs10826223 G 0.86 0.91 0.88 0.92
FIGURE 1 | Scatter plots of PC1 vs. PC2 for CBCS and SCORE.
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EuropeanAmericansandAfricanAmericansweresimilarinterms
of their ancestral structure between CBCS and SCORE. Figure 2
shows the ancestral structure for CBCS and SCORE separately
by case–control status via principal component analysis, show-
ing that cases and controls seemed to be fairly well matched by
ancestry.
Eleven breast cancer GWAS“hits”were tested in CBCS overall
and stratiﬁed by race with and without PS adjustment (Table 2).
Overall CBCS results are shown Table A1 in Appendix. In the
CBCS European Americans, nine of 11 GWAS “hits” were sig-
niﬁcant after adjustment for PC1 only, but after adjustment for
the PC1 by SNP interaction effect, only one SNP remained sig-
niﬁcant [rs1219648 in FGFR2; OR=1.93, 95% CI (1.12,3.36)];
for CBCS African Americans, six of 11 GWAS “hits” were sig-
niﬁcant after adjustment for PC1 only and after adjustment for
the PC1 by SNP interaction effect, all six SNPs remained signif-
icant (although the p-value for signiﬁcance changed from 0.003
to 0.02–0.04 for some SNPs),and an additional SNP now became
signiﬁcant. Interestingly, only six of the nine SNPs signiﬁcant in
European Americans after adjustment for PC1 were signiﬁcant in
African Americans; there was no overlap by race for the GWAS
“hits” that were statistically signiﬁcant after adjustment for the
PC1 by SNP interaction effect. Although in general for CBCS the
p-values for the PC1 by SNP interaction effects were all non-
signiﬁcant, except one SNP for African Americans (rs13281615;
p-value for interaction=0.01).
NineprostatecancerGWAS“hits”weretestedinSCOREoverall
and stratiﬁed by race with and without PS adjustment (Table 3).
Overall SCORE results are shown Table A1 in Appendix. In the
SCORE European Americans, zero out of nine GWAS“hits”were
signiﬁcantafteradjustmentforPC1onlyandnochangeswereseen
after additional adjustment for the PC1 by SNP interaction effect;
for SCORE African Americans,two of the nine GWAS“hits”were
signiﬁcant after adjustment for PC1 only and after adjustment
for the PC1 by SNP interaction effect, only one SNP remained
signiﬁcant [rs16901979 at 8q24; OR=3.24, 95% CI (1.19,8.78)].
Although in general for SCORE the p-values for the PC1 by SNP
interaction effects were all non-signiﬁcant.
DISCUSSION
We investigated the importance of adjustment for PS effects using
principalcomponentsanalysisontwolargeepidemiologicdatasets
of breast and prostate cancer that include both European and
African Americans. In addition, we show the importance of addi-
tionallyadjustingforapotentialSNPbyPSinteractioneffect.Our
results show that PS, in particular PS by GWAS “hit” interaction
effects, can greatly change the signiﬁcance of these GWAS “hits”
by racial group. We also show that the ﬁrst principal component
explains the majority of the ancestral variation by race in each
study population; for CBCS PC1 explained 53.7% of the vari-
ance and for SCORE PC1 explained 49.5% of the variance and
the remaining PCs each accounted for <1% of the variance for
each study site. In a completely random matrix with no struc-
ture,having 136 dimensions (i.e.,136 AIM SNPs),each PC would
account for ∼0.7% of the variance, which is what we see for
all PC’s beyond PC1 for the joint analysis and for each speciﬁc
study site individually. PS can cause both false positive and false
negative associations in epidemiologic studies of individuals with
mixed ancestry. There are now multiple examples in the literature
about the importance of adjustment for PS and how PS can affect
study inference in recently admixed populations such as African
Americans or Hispanic Americans (e.g., Kittles et al., 2002; Ziv
et al.,2006).
Multiple GWAS have now been performed for many complex
diseases including breast and prostate cancers. The vast majority
of these studies have been performed in individuals of European
ancestryonly;breastcancer(Eastonetal.,2007;Hunteretal.,2007;
Stacey et al., 2007; Gold et al., 2008; Ahmed et al., 2009; Thomas
etal.,2009;Zhengetal.,2009c)andprostatecancer(Amundadottir
etal.,2006;Freedmanetal.,2006;Dugganetal.,2007;Gudmunds-
son et al., 2007, 2009; Haiman et al., 2007; Yeager et al., 2007,
2009; Sun et al., 2008; Thomas et al., 2008; Al Olama et al., 2009;
Eeles et al., 2009; Hsu et al., 2009; Lou et al., 2009; Zheng et al.,
2009a). We showed in this study that association statistics for dif-
ferent racial groups can be impacted when adjustment for PS and
an interaction between PS and the SNP of interest is performed.
Further replication studies of the GWAS “hits” included in this
FIGURE 2 | Scatter plots of PC1 vs. PC2 for CBCS and SCORE by case–control status.
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analysis and others have been performed in African Americans
with breast cancer (Zheng et al., 2009b; Barnholtz-Sloan et al.,
2010)andprostatecancer(Robbinsetal.,2007;Hookeretal.,2009;
Watersetal.,2009;Xuetal.,2009;Changetal.,2011;Table 4).One
of these studies was based on the CBCS population (Barnholtz-
Sloan et al., 2010) and another included the SCORE population
as one of many studies used for analysis (Chang et al., 2011).
Although these studies used different AIMs panels and different
techniques for ancestry/PS estimation, all studies showed that PS
adjustment did affect the magnitude of association statistics and
was therefore a necessary adjustment factor. Additionally, Chang
et al. (2011) showed that for those study sites included in their
analysisthathadavailablePSancestryinformationthattheaverage
ancestry varied signiﬁcantly by study site. Hence, they concluded
that adjustment for study site would also serve as a partial proxy
for PS adjustment.
InthisstudyweshowthattheadditionaladjustmentforaPSby
SNP interaction effect changes the magnitude and signiﬁcance of
most association statistics in both racial groups studied, particu-
larlyfortheCBCSstudy,althoughthep-valuesforthisinteraction
were non-signiﬁcant. For CBCS European Americans, all but one
SNPwerenon-signiﬁcantafteradjustmentforthePSbySNPinter-
actioneffectwherethemagnitudeof theinteractionORwasmuch
higher than previously reported in other studies at 1.93. For the
six of the seven SNPs that remained signiﬁcant in CBCS African
Americans after adjustment for the PS by SNP interaction effect
theirassociationstatisticscorroboratedwithpreviouslypublished
studies in African Americans (Table 4) in terms of their direc-






Americans only one SNP remained signiﬁcant after PS by SNP
interaction effect adjustment (rs16901979). Interestingly, in pre-
vious prostate cancer case–control studies of African Americans,
rs16901979 was the only SNP that showed a consistent signiﬁcant
effect in multiple studies (Table 4).
The SNPs used in this analysis were all highly selected given
they had been previously shown to be associated with breast or
prostatecancerinpreviousGWASstudies,irrespectiveof thisfact,
this analysis showed that PS can cause inﬂation and deﬂation
of the signiﬁcance of association statistics. Additionally, some of
the affects on association statistics after adjustment for PS or
for the PS by SNP interaction effect could have also been due
to issues related to study design, since cases and controls can-
not be perfectly matched for allele frequency within each racial
group. We did not perform haplotype analyses in this study as
out goal was limited to single SNP replication of GWAS hits pre-
viously reported in European and African Americans; however
haplotype analyses could have been informative to show further
differences in genetic associations by race. There may be other
relevant SNPs within these loci that are associated with breast or
prostate cancer, particularly for different racial groups that were
not examined. In addition, our sample size was relatively small
for African Americans, particularly in the SCORE study. We also
realize that there are many additional factors that may potentially
inﬂuence a GWAS replication study that were not adjusted for in
this analysis; we adjusted for the same factors as previous studies
inordertoreplicatepreviousﬁndings.Futureresearchwillrequire
pooling of data from different breast and prostate cancer studies
fordifferentracialgroupsinordertogainamorecompleteunder-
standing of differences in risk alleles by race and in order to study
gene–gene and gene–environment interaction.
In conclusion, we demonstrated that genetic associations by
race are modiﬁed by interactions between individual SNPs and PS
and that signiﬁcance of particular GWAS “hits” is not the same
between racial groups. Our results and results of previously pub-
lished studies in African Americans as shown in Table 4 highlight
the need to conduct GWAS and GWAS replication studies in a
variety of racial groups.
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APPENDIX
TableA1 | Assessment of population stratiﬁcation adjustment on GWAS hit association results for CBCS and SCORE.
Gene or region Risk allele N cases N controls Age and race Age, race, and PC1
Dataset SNP OR (95% CI) p-Value OR (95% CI) p-Value
CBCS* rs2981582 FGFR2 C 1946 1747 1.26 (1.14,139) <0.0001 1.26 (1.14,1.39) <0.0001
rs1219648 A 1945 1747 1.26 (1.15,1.39) <0.0001 1.26 (1.15,1.39) <0.0001
rs2420946 C 1944 1744 1.25 (1.13,1.38) <0.0001 1.25 (1.13,1.38) <0.0001
rs11200014 G 1946 1747 1.22 (1.10,1.36) <0.0001 1.23 (1.10,1.36) 0.0001
rs2981579 C 1946 1747 1.29 (1.17 ,1.42) <0.0001 1.29 (1.17 ,1.42) <0.0001
rs2162540 A 1944 1746 1.28 (1.16,1.41) <0.0001 1.28 (1.16,1.41) <0.0001
rs3135718 A 1946 1745 1.29 (1.17 ,1.42) <0.0001 1.29 (1.17 ,1.42) <0.0001
rs2936870 C 1945 1747 1.29 (1.17 ,1.42) <0.0001 1.29 (1.17 ,1.42) <0.0001
rs2912774 C 1944 1744 1.29 (1.17 ,1.42) <0.0001 1.29 (1.17 ,1.42) <0.0001
rs1896395 C 1946 1747 1.03 (0.85,1.24) 0.77 1.03 (0.85,1.25) 0.77
rs13281615 8q24 A 1934 1746 1.07 (0.97 ,1.18) 0.19 1.07 (0.97 ,1.18) 0.19
SCORE rs1447295 8q24 C 790 322 1.33 (1.02,1.73) 0.04 1.33 (1.02,1.74) 0.03
rs4242384 A 792 322 1.34 (0.99,1.81) 0.06 1.34 (0.99,1.81) 0.06
rs16901979 C 789 322 1.42 (1.10,1.82) 0.007 1.49 (1.14,1.94) 0.003
rs10486567 JAZF1 C 775 315 0.92 (0.73,1.16) 0.50 0.93 (0.74,1.17) 0.52
rs7920517 MSMB G 793 322 0.77 (0.63,0.94) 0.01 0.76 (0.62,0.94) 0.01
rs10993994 T 778 315 0.81 (0.67 ,0.99) 0.04 0.81 (0.66,0.99) 0.04
rs7904463 C 773 316 0.97 (0.79,1.19) 0.76 0.98 (0.80,1.20) 0.83
rs10740051 G 780 315 0.92 (0.72,1.18) 0.53 0.91 (0.71,1.17) 0.48
rs10826223 G 769 315 1.29 (0.91,1.82) 0.15 1.29 (0.91,1.83) 0.14
*Additionally adjusted for a study design offset term.
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